VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

C. muridarum MOMP protein vaccine
Vaccine Information
  • Vaccine Name: C. muridarum MOMP protein vaccine
  • Target Pathogen: Chlamydia muridarum
  • Vaccine Ontology ID: VO_0011453
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: C. muridarum major outer membrane protein MOMP
  • MOMP gene engineering:
    • Type: Recombinant protein preparation
    • Description: Recombinant maltose binding protein-MOMP (MBP-MOMP) was cloned into the bacterial expression vector pMAL-c2, and used to transform Escherichia coli (DH5α[pMMM3]). The MBP-MOMP was purified by passage through a PD-10 column (Amersham Biosciences, NSW, Australia), followed by a Sephadex G-75 column (Sigma–Aldrich) (Skelding et al., 2006).
    • Detailed Gene Information: Click Here.
  • Adjuvant: cholera toxin
  • Adjuvant: CpG DNA vaccine adjuvant
  • Immunization Route: Intranasal immunization
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Groups of five mice were immunized on days 0, 7, 14, and 35 via either the IN or TCI route. One group of five mice were used as a control, receiving no immunization solution. Mice immunized intranasally were anaesthetised via inhalation of 4% isofluorane (Abbott Australasia, NSW, Australia), and 10 μl of immunization solution containing 100 μg MOMP, admixed with 10 μg CpG-ODN 1826 (5′-TCC ATG ACG TTC CTG ACG TT-3′) (Geneworks, SA, Australia), and 10 μg cholera toxin (Sigma–Aldrich) was gently pipetted onto each nare (5 μl per nare) (Skelding et al., 2006).
  • Challenge Protocol: Five days after the final boost, mice were infected intranasally with C. muridarum. Mice were anaesthetised with 4% isoflurane and 103 IFUs were gently pipetted onto the nares. Mice were weighed daily for 10 days then sacrificed 10 days post-infection via a sodium pentobarbital overdose (Nembutal, Abbott Australasia). The lungs from the mice were either perfused and fixed for histopathology or collected for determination of C. muridarum levels (Skelding et al., 2006).
  • Efficacy: Both intranasal and transcutaneous immunization protected mice against respiratory challenge with Chlamydia (Skelding et al., 2006).
  • Host Ifng (Interferon gamma) response
    • Description: Both TCI and IN immunization resulted in greatly increased IFN-γ gene expression in stimulated lymph node cells (stimulated with MOMP) as compared to non-immunized mice (Skelding et al., 2006).
    • Detailed Gene Information: Click Here.
  • Host IgA response
    • Description: Both routes of immunization induced a significant MOMP-specific IgA response in serum with the highest IgA response seen in animals immunized intranasally. These results were compared 7 days post-immunization to non-immunized control mice (Skelding et al., 2006).
    • Detailed Gene Information: Click Here.
  • Host IgG response
    • Description: Both routes of immunization (TCI and IN) resulted in levels of MOMP-specific IgG in serum that were significantly higher than that in serum of non-immunized control mice. There was no significant difference between serum IgG levels in animals immunized by either route. These results were gathered 7 days post-immunization (Skelding et al., 2006).
    • Detailed Gene Information: Click Here.
References
Skelding et al., 2006: Skelding KA, Hickey DK, Horvat JC, Bao S, Roberts KG, Finnie JM, Hansbro PM, Beagley KW. Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection. Vaccine. 2006; 24(3); 355-366. [PubMed: 16153755].